Priyanka Rohatgi

Priyanka Rohatgi is a Venture Partner at Longwood Fund, where she focuses on early-stage life sciences and biotechnology investments and company creation. Prior to her current position, she served as a Partner at several prominent corporate venture capital arms, including Novo Ventures, Ipsen Ventures, AbbVie Ventures, and Baxter Ventures. Throughout her career, she has held board member or observer roles at more than ten biotechnology companies, guiding multiple startups through public offerings and acquisitions. Her portfolio experience includes involvement with Precision Bioscience (NASDAQ: DTIL), Pyxis Oncology (NASDAQ: PYXS), and Syntimmune, which was acquired by Alexion. In addition to her investment activities, she mentors life sciences entrepreneurs at Endless Frontier Labs and frequently advises biotech founders as a fractional Chief Business Officer. Her career centers on bridging scientific research with venture capital to advance early-stage drug discovery.